<SUBMISSION>
<ACCESSION-NUMBER>0001193125-09-223278
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20091104
<ITEMS>1.01
<ITEMS>2.03
<ITEMS>3.02
<ITEMS>9.01
<FILING-DATE>20091104
<DATE-OF-FILING-DATE-CHANGE>20091104
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>PRO PHARMACEUTICALS INC
<CIK>0001133416
<ASSIGNED-SIC>2834
<IRS-NUMBER>043562325
<STATE-OF-INCORPORATION>NV
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>001-31791
<FILM-NUMBER>091156673
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>189 WELLS ST
<STREET2>STE 200
<CITY>NEWTON
<STATE>MA
<ZIP>02459
<PHONE>6175590033
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>189 WELLS ST
<STREET2>STE 200
<CITY>NEWTON
<STATE>MA
<ZIP>02459
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:3px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE
COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px"
ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>Form 8-K </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>Current Report
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 </B></FONT></P> <P
STYLE="margin-top:8px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>November&nbsp;4, 2009 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman"
SIZE="3"><B>Date of Report </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Date of earliest event reported) </B></FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>PRO-PHARMACEUTICALS, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of Registrant
as specified in its charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Nevada</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>000-32877</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>04-3562325</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction of</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"
ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>incorporation or organization)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission File Number)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7 Wells Avenue </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Newton, Massachusetts 02459 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal
executive offices) (Zip code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(617) 559-0033 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s telephone number, including area code) </B></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman"
SIZE="1"><B>(Former name or former address, if changed since last report) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the
appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;1.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Entry into a Material Definitive Agreement </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In a Current Report on Form 8-K filed with the Commission on February&nbsp;18, 2009 (the &#147;<U>February 18, 2009 Form 8-K Current Report</U>&#148;), Pro-Pharmaceuticals, Inc., a Nevada corporation (the
&#147;<U>Company</U>&#148;), reported, among other things, that the Company (i)&nbsp;had entered into a Securities Purchase Agreement (the &#147;<U>Purchase Agreement</U>&#148;) and related agreements on February&nbsp;12, 2009 with 10X Fund, L.P., a
Delaware limited partnership (the &#147;<U>Purchaser</U>&#148;) and (ii)&nbsp;had completed an initial closing under the Purchase Agreement. The February&nbsp;18, 2009 Form 8-K Current Report also reported that under the Purchase Agreement the
Company agreed to issue and sell to the Purchaser, and the Purchaser agreed to purchase, at one or more subsequent closings: (i)&nbsp;up to 2,100,000 shares of Series B-2 Preferred Stock (the &#147;<U>Series B-2 Preferred Stock</U>&#148;)
convertible into up to 8,400,000 shares of the Company&#146;s common stock, par value $0.001 per share (the &#147;<U>Common Stock</U>&#148;); (ii)&nbsp;Class&nbsp;A-1 Warrants exercisable to purchase up to 4,200,000 shares of Common Stock (the
&#147;<U>Class A-1 Warrants</U>&#148;); (iii)&nbsp;Class&nbsp;A-2 Warrants exercisable to purchase up to 4,200,000 shares of Common Stock (the &#147;<U>Class A-2 Warrants</U>&#148;); and (iv)&nbsp;Class B Warrants exercisable to purchase up to
16,800,000 shares of Common Stock (the <U>Class B Warrants</U>&#148;) for an aggregate purchase price of $4.2 million (less the origination fees and expenses described below). </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On August&nbsp;11, 2009, the Company and the Purchaser entered in to a letter agreement (the &#147;Letter Agreement&#148;), pursuant to
which the parties amended the Purchase Agreement and agreed to the terms of an amendment to the Certificate of Designation of Preferences, Rights and Limitations for the Series B-1 Convertible Preferred Stock and Series B-2 Convertible Preferred
Stock (the &#147;Designation Certificate Amendment&#148;). Among the changes contained in the terms of the Letter Agreement and the Designation Certificate Amendment was an extension of the final purchase date under the Purchase Agreement from
August&nbsp;11, 2009 to February&nbsp;11, 2010. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In a subsequent closing on November&nbsp;4, 2009, pursuant to the Purchase
Agreement, the Company issued and sold an aggregate of (i)&nbsp;155,000 shares of Series B-2 Preferred Stock convertible into 620,000 shares of Common Stock, (ii)&nbsp;Class&nbsp;A-1 Warrants exercisable to purchase 310,000 shares of Common Stock,
(iii)&nbsp;Class&nbsp;A-2 Warrants exercisable to purchase 310,000 shares of Common Stock, and (iv)&nbsp;Class B Warrants exercisable to purchase 1,240,000 shares of Common Stock for gross proceeds of $310,000. Net proceeds of these sales were
approximately $296,000 after reimbursement of the Purchaser&#146;s expenses (including legal expenses) in connection with the subsequent closings and an origination fee in the amount of three percent of the gross proceeds from the sale of these
securities. The terms and conditions of the Purchase Agreement, the Certificate of Designation of Preferences, Rights and Limitations for the Series B-1 Convertible Preferred Stock and Series B-2 Convertible Preferred Stock, the &#147;Original
Designation Certificate&#148;, that established the Series B-2 Preferred Stock, the Series A-1 Warrants, the Series A-2 Warrants and the Series B Warrants were disclosed in the February&nbsp;18, 2009 Form 8-K Current Report including the exhibits
thereto. The terms and conditions of the Letter Agreement and the Designation Certificate Amendment were described in the Company&#146;s Quarterly Report on Form 10-Q for the quarter ended June&nbsp;30, 2009, and copies of the Letter Agreement and
Designation Certificate Amendment were filed as exhibits thereto. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The description of the Class&nbsp;A-1 Warrants, the
Class&nbsp;A-2 Warrants and the Class B Warrants issued by the Company in the subsequent closing reported in this report is not complete and is qualified in its entirety by reference to the full text of the Form of Class&nbsp;A-1 Warrants, the Form
of Class&nbsp;A-2 Warrants and the Form of Class B Warrants, copies of which are filed as Exhibit 4.1, Exhibit 4.2 and Exhibit 4.3, respectively, in the February&nbsp;18, 2009 Form 8-K Current Report and incorporated herein by reference. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;2.03</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Creation of Direct Financial Obligation or an Obligation under an Off-Balance Arrangement of Registrant. </B></FONT></TD></TR></TABLE> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the terms of the Original Designation Certificate, as amended by the Designation Certificate Amendment, upon notice of not less than 30
trading days, a holder may require the Company to redeem, in whole or in part, (i)&nbsp;the Series B-1 Preferred Stock at any time on or after September&nbsp;12, 2010 and (ii)&nbsp;the Series B-2 Preferred Stock at any time on or after two years
from the date of issuance of such shares of Series B-2 Preferred Stock. The redemption price will be equal to the sum of the stated value of the Series B Preferred Stock, plus all accrued but unpaid dividends thereon, as of the redemption date.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the Company fails for any reason to pay the redemption price in cash on the redemption date, then the holders requesting
redemption may, at their sole option, automatically convert their shares of Series B Preferred Stock into a promissory note bearing interest at the rate of 15%&nbsp;per year and secured by a lien on all assets of the Company. The Company has
executed a promissory note, security agreement and escrow agreement, copies of which were filed as Exhibits 10.2, 10.3 and 10.4, respectively, to the February&nbsp;18, 2009 Current Report on Form 8-K and are incorporated herein by reference, which
will be held in escrow and released to the holders upon the occurrence of such an event. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;3.02</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Unregistered Sales of Equity Securities. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The information contained in Item&nbsp;1.01 of this report is incorporated by reference into this Item&nbsp;3.02. The Series B-2 Convertible Stock and warrants sold at the subsequent closing on
November&nbsp;4, 2009, under the Purchase Agreement were issued in reliance on the exemption from registration under Section&nbsp;4(2) of the Securities Act of 1933, as amended (the &#147;<U>Securities Act</U>&#148;), and Rule 506 of Regulation D
promulgated thereunder. The Series B-2 Preferred Stock and warrants were not registered under the Securities Act and are &#147;restricted securities&#148; as such term is defined in Rule 144 under the Securities Act. </FONT></P> <P
STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Statements and Exhibits. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) Financial Statements of Businesses Acquired. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Not applicable.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Pro Forma Financial Information. </FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Not applicable. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(c) Shell Company Transactions </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Not applicable. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Exhibits. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="91%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;4.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Class A-1 Common Stock Purchase Warrant*</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;4.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Class A-2 Common Stock Purchase Warrant*</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;4.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Class B Common Stock Purchase Warrant*</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">News release dated November 4, 2009, &#147;Pro-Pharmaceuticals Closes $310,000 Tranche Brings Total to $4.1 Million of $6 Million Private Placement.&#148;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the Company&#146;s Current Report on Form 8-K filed with the Commission on February&nbsp;18, 2009. </FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURE </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">PRO-PHARMACEUTICALS, INC.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/<SMALL>S</SMALL>/&nbsp;&nbsp;&nbsp;&nbsp;A<SMALL>NTHONY</SMALL> D.
S<SMALL>QUEGLIA&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</SMALL></FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Anthony D. Squeglia</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Chief Financial Officer</B></FONT></P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: November&nbsp;4, 2009 </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:28pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;4.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Class&nbsp;A-1 Common Stock Purchase Warrant.*</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;4.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Class&nbsp;A-2 Common Stock Purchase Warrant.*</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;4.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Class B Common Stock Purchase Warrant.*</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">News release dated November 4, 2009, &#147;Pro-Pharmaceuticals Closes $310,000 Tranche Brings Total to $4.1 Million of $6 Million Private Placement.&#148;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incorporated by reference to the Company&#146;s Current Report on Form 8-K filed with the Commission on February&nbsp;18, 2009. </FONT></TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dex991.htm
<DESCRIPTION>NEWS RELEASE DATED NOVEMBER 4, 2009
<TEXT>
<HTML><HEAD>
<TITLE>News release dated November 4, 2009</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px">

<IMG SRC="g77312image002.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:14px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>PRO-PHARMACEUTICALS CLOSES $310,000 TRANCHE; </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>BRINGS TOTAL TO $4.1 MILLION OF $6.0 MILLION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>PRIVATE PLACEMENT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Newton, MA (November 4, 2009) Pro-Pharmaceuticals, Inc. (OTCBB:
PRWP)</B> (the &#147;Company&#148;), today announced that it has closed a $310,000 tranche of a private placement of up to $6.0 million with 10X Fund, L.P., which is purchasing unregistered Series B convertible preferred stock and warrants. This
tranche brings the total raised to date from the 10X Fund to approximately $4.1 million. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">At the closing, which occurred on November&nbsp;4,
2009, the Company issued and sold 155,000 shares of Series B-2 preferred stock convertible into 620,000 shares of common stock, a Class&nbsp;A-1 and a Class&nbsp;A-2 warrant each exercisable to purchase 310,000 shares of common stock and a Class B
warrant exercisable to purchase 1,240,000 shares of common stock, for a gross purchase price of $310,000. Net proceeds were approximately $296,000. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman"
SIZE="2">The Company expects to use the proceeds from the financing for partnership development and approvals in countries with their own approval process, as well as for general corporate purposes. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Series B Preferred Stock, the Class&nbsp;A-1 Warrants, the Class&nbsp;A-2 Warrants and the Class B Warrants, including the common stock underlying the
Series B Preferred Stock and warrants, have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px;padding-bottom:3px;"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About DAVANAT<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and Galectin Therapeutics </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:3px;"><FONT STYLE="font-family:Times New Roman"
SIZE="2">DAVANAT<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, the Company&#146;s lead product candidate, is a carbohydrate polymer that targets galectin
receptors that are over-expressed on cancer cells. Current research indicates that galectins affect cell development and play important roles in cancer, including tumor cell survival, angiogenesis and tumor metastasis.&nbsp;To date, DAVANAT<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> has been administered to approximately 100 cancer patients. Data from a Phase II trial for end-stage colorectal
cancer patients showed that DAVANAT<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> in combination with 5-FU extended median survival to 6.7 months with
significantly reduced side effects, as compared to 4.6 months for best standard of care as determined by the patients&#146; physicians. These clinical trials also showed that patients experienced fewer serious adverse side effects of the
chemotherapy and required less hospitalization. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Pro-Pharmaceuticals, Inc. </B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pro-Pharmaceuticals, OTCBB: PRWP, is engaged in the discovery, development and commercialization of carbohydrate therapeutics for advanced treatment of
cancer and fibrosis.&nbsp;Initially, the product pipeline is focused on increasing the efficacy and decreasing the toxicity of chemotherapy drugs.&nbsp;The Company is headquartered in Newton, Mass.&nbsp;Additional information is available at
www.pro-pharmaceuticals.com. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FORWARD LOOKING STATEMENTS:</B> Any statements in this news release about future expectations, plans and
prospects for the company, including without limitation statements containing the words &#147;believes,&#148; &#147;anticipates,&#148; &#147;plans,&#148; &#147;expects,&#148; &#147;intends,&#148; and similar expressions, constitute forward-looking
statements as defined in the &#147;safe harbor&#148; provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management&#146;s current expectations and are subject to a number of factors and
uncertainties, which could cause actual results to differ materially from those described in such statements. We caution investors that actual results or business conditions may differ materially from those projected or suggested in forward-looking
statements as a result of various factors including, but not limited to, the following: uncertainties as to the utility and market for our potential products; uncertainties associated with pre-clinical and clinical trials of our product candidates;
and uncertainties as to the results of the financing. More information about those risks and uncertainties is contained in the Company&#146;s most recent quarterly or annual report and in the Company&#146;s other reports filed with the Securities
and Exchange Commission. While the Company anticipates that subsequent events may cause the Company&#146;s views to change, the Company disclaims any obligation to update such forward-looking statements. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contact: Pro-Pharmaceuticals, Inc., Anthony D. Squeglia: 617.559.0033; squeglia@pro-pharmaceuticals.com. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">DAVANAT is a registered trademark of Pro-Pharmaceuticals. </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g77312image002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g77312image002.jpg
M_]C_X``02D9)1@`!`0$`>`!X``#_X0!H17AI9@``24DJ``@````#``!1!``!
M``````````11`0`!`````````&F'!``!````,@`````````!`(:2`@`;````
M1`````````!3;V9T=V%R93H@36EC<F]S;V9T($]F9FEC90``_]L`0P`(!@8'
M!@4(!P<'"0D("@P4#0P+"PP9$A,/%!T:'QX=&AP<("0N)R`B+",<'"@W*2PP
M,30T-!\G.3TX,CPN,S0R_]L`0P$)"0D,"PP8#0T8,B$<(3(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R_\``$0@`
M-`%N`P$B``(1`0,1`?_$`!\```$%`0$!`0$!```````````!`@,$!08'"`D*
M"__$`+40``(!`P,"!`,%!00$```!?0$"`P`$$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$`!\!``,!`0$!`0$!`0$````````!`@,$!08'"`D*"__$`+41``(!
M`@0$`P0'!00$``$"=P`!`@,1!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:``P#
M`0`"$0,1`#\`]_HHHH`****`"BJJ:E82ZC+I\=[;/?1+ODMEE4R(O')7.0/F
M'/N/6JWB.[GL/#&K7EL^RXM[*:6)\`[65"0<'@\CO5<KND!F>+O'&D>$+8_:
MY/-OGC+P6:?>DYP,G&%&>Y]#C)&*\6L/''B'6/$YU&XU&1)8HF$20_(D:EU;
M:%[C@9W9)"C).*XN[O+F_N7N;RXFN+A\;I9G+LV!@9)Y/``K2\-_\A&3_KD?
MYBO8HX6%-:ZLBH_=9]%^&?&5IKVRUE7R+\)ED/W9".NP_K@\_7!-=-7SS'(\
M4B21NR2(0RLIP5(Z$'UKVKP?=W%]X5L;BZE:69@REVZG#L!GU.`.:X<5AU3]
MZ.Q%*HY:,W****XS8****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`**@N[RUT^U>ZO;F&VMTQOEF<(BY.!DG@<D#\:+2
M\M=0M4NK*YAN;=\[)87#HV#@X(X/((_"G9VN!/1112`****`"BBB@`HHHH`^
M;KQ].FU;QYIDFF3:AK%[J3+IR6\.^5"LLK.P;:2%`"[@.6''`RP]FU**\@^$
MMY#J!<WT>A.MP7?>QD$!#9;)R<YYSS3_``QX/_X1O7/$&I?;OM']KW/G^7Y.
MSROF=L9W'=]_K@=*V]8T_P#M;0]0TWS?*^UVTD'F;=VS>I7.,C.,],UZ&(Q4
M9SBH[*SO\E_D7*5V>!>%[.V\3:-H&G:!8?9_$>EWJSW6I;81MA,C'?M+AI=O
M[O@J<8QD;N?4OBQXAO/#O@EY;!WBN;N=;59T;:T0(9BPXZX4CC!&[(.156Q^
M%_\`9<.@7&GZQY6KZ1YB"[>VWQS1.[L4:/?Q_K&&0V<$]\;>H\5^&K7Q9X>N
M-)NF\OS,-%,$#-$XY##/Y'&"02,C-76Q%*=>,MXIO\_RZI?(;DFSC?%/PR\-
MV'P[U**PLTAN;2!KM;QP7E9HUR<MD<,%(P/E!;(7(K2M-;G\1?!:ZU2Z&+B7
M2KE93D?,R*Z%N``,E<X`XSBLIO`GC?5H9-&\0>+89]!^52(H%:>94=2H8E`5
M8A<EMS<]=W->BPZ=9V^EQZ8ENALHX1;K"_SKY87;M.<Y&..>M95JB4%&4N9W
MO?71?/O^A+>ECX_8D*2`20.@[UZ-HF@>$(KUV@\;^>WED%?[*E7`R.<DUY[-
M#+;SR03QO%+&Q1XW4JRL#@@@]"#6KX;_`.0C)_UR/\Q7IRBWL[?<93^%G63*
MB7$J12>;$LC*DFW;O4$@-CMD8..V:]C\"_\`(FV'_;3_`-&-7C->U>#+>:U\
M)V4-Q#)#*OF;DD4JP_>,>0:X\=_#2\S"A\1X?:MX;UCX::?H%AIZ77C&:?;'
MY%L5D!\UFR\F`"OE\<D@9!(&W(]/^)"7D7P<O(]0E2:^6"V6XD085Y!+'N(X
M'!.>P^E=+X2\/_\`"+>&+/1OM7VK[-O_`'WE[-VYV;IDX^]CKVH\6^'_`/A*
M?#%YHWVK[+]IV?OO+W[=KJW3(S]W'7O6=3%QE7BU\*E>^_7\%Y':Y:GGO_":
M?\6L_LS_`(1GQ'_R!?L_VK[!^X_U&W?OW?<[YQTYKT+P=_R)&@?]@VW_`/1:
MT?\`"/\`_%$?\(W]J_YAOV#[1Y?_`$SV;]N?QQG\:?#HLMOX/CT*"^>*:.P%
MFEXBE65A'L$@`/!!YQG\:QJU*<XVCIK_`$Q-IGC.MWM]>^(=5^(5H)I;31M6
M@M83%>+Y;P)E9`#UVN3'T&,3-][DU[U#-%<01SP2)+#(H=)$8,K*1D$$=01W
MK@+3X,^$H='2TN;::XN_+*O>B9T<L?X@H.T8SP"#T&<\D]7X7T67P[X;LM)F
MOGOFM5*"=U*DKN)48).``0H&>@%:8NK1J12@_ATVZ?C^FXY-/8\,T:WTCQ+X
M)L?"UIH6SQ-+F:'4)4CA1U$[;F\S<'D4)N!`5ONG`^7(]]UC4/[)T/4-2\KS
M?LEM)/Y>[;OV*6QG!QG'7%<4/A5:IX<T>SBU'RM8TB0R6NJ);C/^M,FUHR2&
M4%N`3P>>A(/5Z[I-YK7A>ZTH:@EM<W4`AEN4M]RX.`^$+<!AN'WLC/7(IXJM
M3JS5GI=]^KW]+=.@2:;/&?AIXAG\$1ZQ;:O'Y44VFKJEFD]R(TF(7*K'G(+2
M!@,CG]W@@D8&I\'_`.U--\7ZC8W_`.\_M/38M3,[[BTF2I4ACU_USACS\RGG
M@YZK7_A98>(-*T"TGOGBFTJ".V>XBA7=<1*H!'/W3D97DA=S<'-;T_AJ>3Q[
M;>)HM2\I([(V4UIY`;S5W,WW\_+\Q4\#^'KS6U7%49QE;>2UWZ;??_PXW),R
M/BGJUS9^%TTG3]CZCK4ZV$,9D4,5?AB`W4$80GC&\'(XJE\/9CHGBCQ+X,>1
M/)LY_M=A$K.^R"3!*[FZ!0T?'7<S'GK6OXG\"0>+?$.FWNJ7?FZ99QNO]G^6
M5WLV<MYBL&'1..?N>YJ#3?AKI6@^*[+6M"FFL(HHY([BS#M(EP&!QDLV1@D'
M'(.U>`1DX1J45A_9MZM-[=>FOHK;==Q75K&7X]E_M_QSX;\%O/-%97.Z[OHP
M,).BY94)!#?\LG'8#<IY(&.UTCPYH^@;_P"RM/AM-\<<3^4,;PF[:6]6^8Y8
M\GN3@5B^,?`R>*+[3-2M;_\`L[4].D#Q7(MUEW`$,`02,X89&3@9;@YI_A/2
M_&5G/+/XH\06U\I4HEM;VZA0<J0^\*IS]X;<8YSFHG*,J$5&5K+5:ZN_X_H)
M[',>++BPM_BU$^H>'[G7(3H0`MK>R6Y96\]OGVGH`,C/^U[UWWAV6UFT*VDL
MM*FTJW.[9936X@>/YCG*#@9.3[YSWK%UWPCJNH>*4U[2/$7]E7`LA9,/L2S[
MEWES]YL#DCMVZ\UT.D6U]9Z9#!J6H?VA=IN\RZ\E8M^6)'R+P,`@?AFE6G"5
M**3U7K_E;\0;T//?@3_R)%[_`-A)_P#T7%1\"?\`D2+W_L)/_P"BXJM0^!?$
MGAR>>U\'Z];6>D7<YE>&Z@$CVI)3+1L0?,.%(`;`QZGYAT_A#PK9^#]!CTRT
M=Y26,LTS]99"`"V/X1@``#L!U.2=L16IRC-Q=^=I^EK[CDUJ<IXA\-:##\1/
M!MK%HFFQV]Q]M\Z)+5`DFV(%=PQ@X/(STKJ/$UG:Z?\`#[7+6RMH;:W33;G9
M%"@1%S&Q.`.!R2?QJ?4_#_\`:/B?0M9^U>7_`&5]H_<^7GS?-0+US\N,9Z'/
MM5W6-/\`[6T/4--\WROM=M)!YFW=LWJ5SC(SC/3-82K7]G=[;_>_T%?8I>#O
M^1(T#_L&V_\`Z+6N`^'OA/1?%^@R>(_$`35]6O9YA-))(P,(QL"%5;`(7YAP
M"H9<8P#7IFCZ?_9.AZ?IOF^;]DMHX/,V[=^Q0N<9.,XZ9K@$^'GB3P[J,J^#
M?$B6&DW<_F36US$)3`.!E-P;<<9Z[3@*"3C(TI5%[Z4N5MZ/RUNM-?\`AAI[
MGH4,5GH^E1PH4M[&S@"@N_RQQHN.6)Z`#J37@4%W>:=>Z?\`%*ZC?R[S6)HV
M@DE\UOL[*5`3IRH$RC<1]U.,5[;J^C7VJ^$)M&.J^7=SVRP37WV=3OX`D/EY
M`&X;A@'C=QTKE)?@QX7DT$6:PO%J(@5/MZ2/DR`#+^66*X)'*^A(!'!JL)6I
M4T_:/=V>G3KVW^;TV"+2W.K\8_\`(D:__P!@VX_]%M6)\)?^28Z/_P!MO_1S
MUKQ>'I1X%/AN:]1V^P-8BY2$J-NPHK;"QY`QGGD@],X&1X2\&:YX6^QVO_"5
M?:M(MM_^@_V<B;MVX_ZS<6'S-N_#'2LDX>PE3YM;WZZZ/R_,6EK&+\0(9['Q
MG8Z]J/AR;7/#]K9>4\88.EO(78O*8CD'$8ZL`OW?F!`KM?"FJ:)J_AZWN?#Z
M0Q6'($$48C\ENK(RCA6R<GUSD9!!.=XGTOQE>ZK:2>'?$%MI]CM"7,<MNKLI
MW??7*G<<'[I*CY1SR<7?"'A6S\'Z#'IEH[RDL99IGZRR$`%L?PC```'8#J<D
MNI.$J$4WJNU]O/I]P-JQO45RGP_O-:O]!GNM9NWO!)=R&RN7MU@,UMA0C[`!
MM#'<1GG!';%=77-4AR2<7T$U8XKX=?\`,V?]C'>?^R5YGXNBU9/C'KNJZ,4^
MTZ1!%J#JSE=T:11!QP1D88Y&1E=PZ\'V?PYX?_L#^UO]*\_^T-2FO_\`5[?+
M\S'R=3G&.O'TJC8^#_L7Q#U+Q7]NW_;;80?9?)QLP(QG?NY_U?3`Z^U=U+$P
MIU9SWNK>NVA2DDVSF_#/B&S\4?%"VU2S=")/#0$L:MN,,GV@;D/`Y!/H,C!'
M!%,\=2W6O_$?0?!<L_E:/<QB[NHT!!GVF1MC$$';B+`QC!;/)`QK^%?AK9^$
MO%E[K%A>N;6X@:&.S>/)B!96^_GD`K@9&<$9)QDVO&/@9/%%]IFI6M__`&=J
M>G2!XKD6ZR[@"&`()&<,,C)P,MP<T>UHJNG%Z6LGV?3[@NKFAH_@SP]X?U%K
M_2M-2UN6@%NS)(Y!0;>,$XS\JDG&2<DG).=ZN4\)Z7XRLYY9_%'B"VOE*E$M
MK>W4*#E2'WA5.?O#;C'.<UHP6>OQ^+[FZEU.&709+8"&S\L+)%-E><[<LN`Q
MR6ZMC'&:Y:B;D^:=[==?N)?J;5%%%8""BBB@`HHHH`XWQQ\/=/\`%ME)+#'#
M:ZNOS1W07'F'`&V3'+#``SR5QQQD'Q'1]!U;3_$DFFW6G7,=[Y3;83&2S@-C
M*X^\/E/(R.*^H*888FG6<QH944HLA4;E4D$@'T)5<_0>E=5'%2IKE>J)E'F5
MCC_"W@:'3/(O]1'FWZ_,L604B/;ZL/7ID\=`:[.BBL*E251WD$8J*L@HHHJ"
M@HHHH`***R)M?BA\40:(T#@RP"3SR1MWMO*1@=<E89F).`-@')8548N6P&O1
M7-V_B:\FG6-M*0+<W=S9V4BW65:2$RY\W*@QAO*;!42>^.,W;3Q)87<%K."\
M<,]@-0:27:%@B(4CS#GY206QV/EOS\M4Z4UNAV9KT5R\GC:UCTW3;Y["\A2Z
MO?LD\-PHCFL_D=R\JY.U0JASDC"-N]CL:CJ,MM/!9V=NEQ?W"O)'%)(8T"(5
M#LS[6P`748`))8<8R0.E-.S069H45SVH^)9]+L4ENM-V7']DW&HRP>>#Y;0B
M,F+<`0>9,;A_=Z'-/_X2JS,MSL1Y(8H+=T*</))-+)$(MK8VL'C"G<1@L0VW
M::/93M>W];!9F]156PFO)H&^W6B6TZMM*QS>:C#`(*MA21SCE5.0>",$Y>G>
M(9;J[$=U9);P3W=Q:6DJ3&0R/"T@8.NT;"1$S#!884@D'`9*$G>W0+&]17'0
M>.)?[*>[N]/MHYFT=]8@MX+TR,8E53B3*+L)+``@,#A_[O.U>:_%8W]Y;2P.
MPMX+:1"A!:5YY)(TC`.`"611DD#YN<`9JG1FG9H+,UZ*Q9]7U&PTNZNM1TR&
M)X=FTPW7F0D,VW+.45D5?O.=A"KR"V"!:L+V\O=*:Y-K;"<KNA\NZ\R"8%0R
MLL@7.TY`R4SD'`(P3+IR2N%C0HKBK'QU=36FI7M]IEG:6FG:D--GD^WEL/YL
M<;/S&H"`2%LD@_+C`SD7?^$N^VOLT:"SO]^I?8(I?MF(GQ;>>7WJC=,%<`'D
M=1TJWAZBZ?D%F=117-V/BQ=7LH/[+MDN+Z9IE6-I2D!$+!9'6;:=\>64*RJ2
M2PX&'VVM-UV>\N-/MKK3)K&XN;:XFEBF<%HFADC0J,<,I,F0PZ@`XYXETIK=
M?U_2"S-JBN>M/$5UJEC8/IFGPR7=Q90WTT4]R8XX4E!VC>$8LQ*L!A<80DE?
ME#0:OXVLM$^W)?+#;7$&FI>PV]S=(DD[-YO[H#D;@8P,J6Y;\VJ,V[):A9G4
M452U+4/L$<*QQ>==7,GDVT1;:'?:S<M@[5"JS$\G"G`8X!JC6+F.73H;O37M
MYKN[:U(,RLHVPO)O0C.Y28R!N"MSD@=*A0DU<5C7HK%O_$'V"^EL&M=UV_E_
M88_,P+K>=IQQD;""S[0VU-K<YVA\&K7EYJ*"ST])=,$\EO+=M<;75TW!B(]O
M*AUV9W`YR0I4!B_9RM<=C7HKGI/$L]O?6;SZ;_Q)[V00V^H03B;#,0(RZJ,*
MDA/RL&;JN[:3@06?C%)['4;Z:VA%O96S7,D=O=++/"%!/ES1$*8I<`_+EAE6
M!88&:]C.U[!9G445BRZS?6EH9[W2O(W7-O%&HN%?*S2K'\V!PZ[LE1E>@#MS
MBCI7BW^T]<DT_.D1[+F>#RO[3S='RF=<^3Y??9G&[A3GFDJ,VFTM$%F=117*
M:5XZL]1TZSOIK=[2&2PGO;D2-N:W$7E$@J!D@K*'!X)7:<?-Q:U'Q#?:5HUQ
MJ%[I<-OLDA6/SKU1'MED5/WCA3L9=V6P&4#&&;G#=":?*UK_`$@LSH:*Y1O&
M+)IUC=K'I5V+G5(M/8V.J"9$#X&[<47<P)'R`9QSG&<:^@ZRFNZ:MZD/E*VU
ME4R*YVNBR(3@_*VQURIZ'.-RX9E*E.*NT%F:E%%%9B"BBB@`HHHH`****`"B
MBB@`HHHH`****`"L6\\)Z)>WS7\EA"+]KF&Y-V$!EW1%"H#$$JN(U!`QP3W)
M-%%73DXRT8T%GX;AM+Y;@WUY/%'<S74-M+Y?EPRRERS*50,?]9(`&8C#>H!$
M<GA'3)++4[3-RL.I3^;<;)B&*EMS1!NHC9C(2N?^6LF,;J**Z9R:GIY?F-[D
M\/AO3;6YM9+.%+.&VG^T1VUM%'''YGER1EB`N22LG//\"XQSED'AN&RTRUL;
M"^O+3[+O6&=?+EE2)FSY0:5&^080`=<(O/%%%*#;E%/R_4$%WX9M;ZU,-S=7
MDA:RN;)Y6D!=EG*EVY&`V4&``%&<!<8`C/A#25N]4NH(WMYM2:&68Q$`":)B
MZ2J""-VX@G.02HR#ELE%+FDM$_ZN@+VG:2+">>YEO+F]NIE2-Y[@(&V(6*KA
M%5<`NYSC/S<DX&*MGX;AM+Y;@WUY/%'<S74-M+Y?EPRRERS*50,?]9(`&8C#
M>H!!15/>H'<C'A.P%I:6GG7/V:"P.G2Q!E`NH-NT"4@9)7D@J5(+-CAB*!X7
MCD34/M>IW]W->P1PF>7RE>$1EV1H]D:@,K.6#$$@@'M115I^ZWZ?^E,8+X:<
M&[E?7=5>ZN5@3[3F%'C6)V=0H6,+@EV!#`Y!Q6CINFIIL<W[^:XGN)/-GGFV
M[Y&VJH)"@*,*JC@#[OKDDHI8A)1=N_Z!(SK7PG86=M?01S7)6\U0:I(69<B4
M2))@<?=S&..N,\U:_L*U_M'[=YDWF_;?MV,C;O\`L_V?'3[NSGUSWQQ116<I
M.[^?Z"!=#A@M6AL[B:U*Y6WEC6-GM4)4M''O5@$)0?*00.`,!5"PGPZ?)MBN
ML:DM[!YH%\3$TK+(X=T(9"FW*IC"C`0`8&02BM*:NDWW_0:(XO"\=I!:1Z?J
M=_9-;VD5F9(O*9I8X@=F[?&PR-S<J!G<<YP,$?A.PCTJXT\37/DSZ7%I;,67
M<(HUD4$<?>Q(V3TX'%%%.3]Q/JW^H=#4O[(7T"H)GMYD;?%<1HC/$V""5WJP
M!*EESCHQK(_X11=N_P#MG4OM?VW[=]KQ!YF_R?(QCR]FW9Q]W.><T44L.ER?
M.P1V-1=-07UG>R3S2W%M;26X=]H\P.8RS,``-V8EZ8')XZ8@_L8B^\Y-2O(K
M7S/-^Q0B*.(MG<22J"3ELL?G^8D@Y!(HHK."UEY)_F)`-#A^U1,UQ,UE!L,&
MGA8UMX2@`4@*H8XQD!F(!P0`57%7_A%;>6>1KV_O[V!K2:R6WN'0JD,I7<NY
M5#L<(HW,Q/ODYHHJ]DVNR`D7PZ7607NL:E>[Y+>0>>8@$,,OF+M5$4#+8#'&
M2`!D8%/T_0GTZ[>2'5[]K9IY9S9NL)CW2,SMR(]^-S$CYO3M116DHKWUT_X"
M'W*L7@O1X_)W)-+Y>DG1VWR?ZVWXX;&/FX/*X^\?;!-X5-TLINM>U>>5_)\M
MWDB`A,<HE4K&L8C+;E&2RDX&,@445--MW;[K\P1=&APS6L4.IW$VIF&Y2ZAE
MNEC#QNA!4KY:J!@CTR<D'(.*NVUI!:>;Y*;3-(99&))9V/<D\G@`#T``&``*
,**YJSM-Q6Q+W/__9
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
